Braskem SA (BAK)       14.95  +0.47 (+3.25%)

14.95  +0.47 (+3.25%)

US1055321053 - ADR


Fundamental Rating

Taking everything into account, BAK scores 7 out of 10 in our fundamental rating. BAK was compared to 123 industry peers in the Chemicals industry. While BAK has a great profitability rating, there are some minor concerns on its financial health. BAK is valued quite cheap, while showing a decent growth score. This is a good combination!




Profitability

Profitability Rating


BAK's Return On Assets of 17.69% is amongst the best returns of the industry. BAK outperforms 95% of its industry peers. The industry average Return On Assets is 4.55%.
BAK has a Return On Equity of 132.55%. This is amongst the best returns in the industry. The industry average is 16.51%. BAK outperforms 98% of its industry peers.

BAK's Profit Margin of 14.02% is amongst the best returns of the industry. BAK outperforms 82% of its industry peers. The industry average Profit Margin is 7.36%.
BAK has a very good Piotroski-F score of 8.00. This indicates a great health and profitability for BAK.
VS Industry

ROA (17.69%) VS Industry: 95% outperformed.

-168.20
35.03

ROE (132.55%) VS Industry: 98% outperformed.

0.51
216.50

Profit Margin (14.02%) VS Industry: 82% outperformed.

-48,500.00
91.93

Valuation

Valuation Rating


The Price/Earnings Ratio is 2.02, which indicates a rather cheap valuation of BAK.
Compared to an average industry Price/Earning Ratio of 12.09, BAK is valued rather cheaply. On top of this BAK is cheaper than 98% of the companies listed in the same industry.
The Forward Price/Earnings Ratio of 5.87 indicates a rather cheap valuation of BAK.
BAK's low PEG Ratio, which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

Compared to an average Enterprise Value to EBITDA ratio of 8.19, BAK is valued rather cheaply. On top of this, BAK has a better ratio than 98% of the companies listed in the same industry.
When comparing the current price to the book value of BAK, we can conclude it is valued correctly. It is trading at 2.68 times its book value.
Compared to an average industry price book ratio of 2.02, BAK is valued more expensive than its industry peers.
VS Industry

Price/Earnings (2.02) VS Industry: 98% outperformed.

68.94
1.40

Price/Book (2.68) VS Industry: 38% outperformed.

1,035.49
0.01

Enterprise Value/ EBITDA (2.17) VS Industry: 98% outperformed.

75.67
0.47

Growth

Growth Rating


BAK shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 2896.81%, which is quite impressive.
The Earnings Per Share has been growing by 36.14% on average over the past 5 years. This is a very strong growth
The Revenue has grown by 59.84% in the past year. This is a very strong growth!
Measured over the past 5 years, BAK shows a quite strong growth in Revenue. The Revenue has been growing by 17.25% on average per year.

BAK is expected to show a decrease in Revenue. In the coming 5 years, the Revenue will decrease by -7.17% yearly.
BAK is expected to show a very negative growth in Earnings Per Share. In the coming 5 years, the EPS will decrease by -44.35% yearly.
The EPS growth is decreasing: in the next 5 years the growth will be less than in the last years.
The Revenue growth is decreasing: in the next 5 years the growth will be less than in the last years.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPS36.14% 69.6% 2896.81% -46.17% -38.56% -44.86% -44.35%
Revenue17.25% 22.12% 59.84% -1.09% -2.66% -5.74% -7.17%

Health

Health Rating


BAK has a very good Piotroski-F score of 8.00. This indicates a great health and profitability for BAK.
A Current Ratio of 1.63 indicates that BAK should not have too much problems paying its short term obligations.
BAK has an Altman-Z score of 2.66. This is not the best score and indicates that BAK is in the grey zone with still only limited risk for bankruptcy at the moment.
BAK has a Altman-Z score comparable to the industry average, which is at 2.79.

When comparing the Current Ratio of BAK to the average industry Current Ratio of 1.97, BAK is less able to pay its short term obligations than its industry peers.
A Quick Ratio of 0.94 indicates that BAK may have some problems paying its short term obligations.
When comparing the Quick Ratio of BAK to the average industry Current Ratio of 1.31, BAK is less able to pay its short term obligations than its industry peers.
BAK has one of the worst Debt to Equity ratios in its industry. 96% of its industry peers require less debt for financing their operations.
VS Industry

Debt/Equity (3.55) VS Industry: 4% outperformed.

8.24
-4.23

Quick Ratio (0.94) VS Industry: 28% outperformed.

0.00
61.90

Current Ratio (1.63) VS Industry: 33% outperformed.

0.00
61.90

Altman-Z (2.66) VS Industry: 46% outperformed.

-251.54
248.04

Dividend

Dividend Rating


With a Yearly Dividend Yield of 18.27%, BAK is a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 2.32, BAK pays a better dividend. On top of this BAK pays more dividend than 100% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.39, BAK pays a better dividend.
On average, the dividend of BAK grows each year by 58.71%, which is quite nice.

BAK pays out 38.98% of its income as dividend. This is a sustainable payout ratio.
BAK has paid a dividend for at least 10 years, which is a reliable track record.
In the last 3 months the price of BAK has falen by -20.77%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
The Dividend Rate of BAK has been growing, while earnings will be declining. This means the dividend growth is most likely not sustainable.
VS Industry

Dividend Yield (18.27%) VS Industry: 100% outperformed.

0.34
18.27
BAK Daily chart

Braskem SA14.95

NYSE:BAK (6/27/2022, 7:19:33 PM)+0.47 (+3.25%)

Chartmill FA Rating
GICS Sector Materials
GICS IndustryGroup Materials
GICS Industry Chemicals
Earnings (Last) 05-11 2022-05-11/amc Earnings (Next) 08-10 2022-08-10
Ins Owners N/A Inst Owners 1.07%
Market Cap 5.96B Analysts 81.18
Valuation
PE 2.02 Fwd PE 5.87
PEG (NY) N/A PEG (5Y) 0.06
P/S 0.28 P/B 2.68
EV/EBITDA 2.17
Profitability
ROA 17.69% ROE 132.55%
PM 14.02 Asset Turnover 1.26
Growth
EPS 1Y 2896.81% EPS 3Y 69.6%
EPS 5Y 36.14% EPS growth Q2Q 55.16%
EPS Next Y -46.17% EPS Next 2Y -38.56%
EPS Next 3Y -44.86% EPS Next 5Y -44.35%
Revenue growth 1Y 59.84% Revenue growth 3Y 22.12%
Revenue growth 5Y 17.25% Revenue growth Q2Q 17.8%
Revenue Next Year -1.09% Revenue Next 2Y -2.66%
Revenue Next 3Y -5.74% Revenue Next 5Y -7.17%
Health
Current Ratio 1.63 Quick Ratio 0.94
Altman-Z 2.66 F-Score 8
Debt/Equity 3.55
Dividend
Dividend Yield 18.27% Dividend Growth 58.71%
DP 38.98% Ex-Date 04-20 2022-04-20 (0.674385)

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA